首頁 › 子宮內膜癌 › 羅德島州 › Providence
Providence, RI 的 子宮內膜癌 臨床試驗
14 項針對 子宮內膜癌 的研究正在 Providence（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
招募中1 期
- Women and Infants Hospital, Providence
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
招募中3 期
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
招募中2 期
- Women and Infants Hospital, Providence
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
招募中2 期
- Women and Infants Hospital, Providence
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
招募中3 期
- Women & Infants Hospital ( Site 5003), Providence
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
招募中1 期
- Women & Infants Hospital of Rhode Island, Providence
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
招募中3 期
- Research Site, Providence
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
招募中1/2 期
- Research Site, Providence
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
招募中2 期
- Women & Infants Hospital, Providence
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Women and Infants Hospital of Rhode Island, Providence
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
招募中2 期
- Women & Infants Hospital, Providence
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
招募中1/2 期
- Women & Infants Hospital, Providence
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Providence
其他城市的 子宮內膜癌 試驗
- Houston, TX68 項研究
- New York City, NY52 項研究
- Boston, MA50 項研究
- Arlington, VA39 項研究
- Nashville, TN38 項研究
- Los Angeles, CA34 項研究
- St. Louis, MO29 項研究
- Philadelphia, PA28 項研究
- San Antonio, TX27 項研究
- Chicago, IL25 項研究
- Columbus, OH25 項研究
- Queens, NY25 項研究
Providence 的其他研究
- 卵巢癌15 項研究
- 肥胖症14 項研究
- 非小細胞肺癌12 項研究
- 癌症（所有類型）12 項研究
- 克隆氏症12 項研究
- 潰瘍性結腸炎11 項研究
- 乳癌11 項研究
- 急性髓系白血病10 項研究
- 轉移性癌症9 項研究
- 過重9 項研究
- 阿茲海默症8 項研究
- 酒精使用障礙 (AUD)8 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。